Neurogene Inc. Share Price

Neurogene Inc. Share Price

NASDAQ: NGNE | Small Cap
$30.43
+$0.09 (0.28%) Last updated on 29 Oct, 2026 | 20:38 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Neurogene Inc. Stock Performance

Open
$30.84
Prev. Close
$30.34
Circuit Range
N/A
Day Range
$30.25 - $31.89
Year Range
$16.00 - $43.39
Volume
4,493
Average Traded
$31.31

Neurogene Inc. Share Price Today

As of 29 October 2026, Neurogene Inc.'s share price is $30.43. The stock opened at $30.84, compared to its previous close of $30.34. During today's trading session, Neurogene Inc.'s share price traded between $30.25 and $31.89, with an average price of $31.07. Over the past 52 weeks, the stock has recorded a high of $43.39 and a low of $16.00. In terms of performance, Neurogene Inc.'s share price has risen by 16.66% over the last six months and is down 11.18% on a year-on-year basis.

Neurogene Inc. Share Price Chart

Line chart of the Neurogene Inc. price trend over the selected period. The price rose overall, ranging from 30.09 to 31.97, ending at 30.43.
$30.25$31.89
L
Show Current Price
H

Neurogene Inc. Stock Fundamentals & Key Indicators

Market Cap
$648.85M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-5.55
Revenue (TTM)
$0.00
Return On Equity (TTM)
-51.17%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-64.63%

Neurogene Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$20.95-$24.74-$30.93-$34.49
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-18.09%-25.02%-11.51%

Neurogene Inc. Annual Profit & Loss

All figures in USD

Particulars202320242025
Revenue$0.00$0.93$0.00
Net Profit-$36.32-$75.14-$90.35
Net Profit MarginN/A-8079.57%N/A
Income ChangeN/A-106.88%-20.24%

About Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Neurogene Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$27.27
$30.43
+9.13%
Sep 2026
$36.01
$27.88
-25.96%
Aug 2026
$33.60
$37.66
+14.84%
Jul 2026
$32.46
$32.79
+4.68%
Jun 2026
$28.57
$31.32
+11.10%
May 2026
$24.88
$28.20
+8.11%
Apr 2026
$21.28
$26.08
+28.98%
Mar 2026
$23.02
$20.22
-13.88%
Feb 2026
$18.11
$23.48
+33.48%
Jan 2026
$20.42
$17.59
-15.29%
Dec 2025
$20.13
$20.77
-1.68%
Nov 2025
$30.52
$21.12
-38.34%

NGNE Share Price FAQs